Cantheon Capital LLC’s General Partner

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a developer of cannabinoid-based medicines, will conduct FDA Phase 2 and Phase 3 clinical trials for its HOPE-1 treatment of Autism Spectrum Disorder (ASD). Cantheon Capital LLC agreed to provide an initial $8.6 million in funding to Zelira to...